1. Home
  2. NAMS vs CIVI Comparison

NAMS vs CIVI Comparison

Compare NAMS & CIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NAMS
  • CIVI
  • Stock Information
  • Founded
  • NAMS 2019
  • CIVI 1999
  • Country
  • NAMS Netherlands
  • CIVI United States
  • Employees
  • NAMS N/A
  • CIVI N/A
  • Industry
  • NAMS Biotechnology: Pharmaceutical Preparations
  • CIVI Oil & Gas Production
  • Sector
  • NAMS Health Care
  • CIVI Energy
  • Exchange
  • NAMS Nasdaq
  • CIVI Nasdaq
  • Market Cap
  • NAMS 2.5B
  • CIVI 2.5B
  • IPO Year
  • NAMS N/A
  • CIVI 2011
  • Fundamental
  • Price
  • NAMS $19.85
  • CIVI $29.72
  • Analyst Decision
  • NAMS Strong Buy
  • CIVI Buy
  • Analyst Count
  • NAMS 8
  • CIVI 12
  • Target Price
  • NAMS $42.88
  • CIVI $46.60
  • AVG Volume (30 Days)
  • NAMS 1.0M
  • CIVI 2.7M
  • Earning Date
  • NAMS 08-06-2025
  • CIVI 07-31-2025
  • Dividend Yield
  • NAMS N/A
  • CIVI 10.16%
  • EPS Growth
  • NAMS N/A
  • CIVI 5.61
  • EPS
  • NAMS N/A
  • CIVI 8.73
  • Revenue
  • NAMS $47,140,000.00
  • CIVI $5,071,808,000.00
  • Revenue This Year
  • NAMS N/A
  • CIVI N/A
  • Revenue Next Year
  • NAMS N/A
  • CIVI N/A
  • P/E Ratio
  • NAMS N/A
  • CIVI $3.40
  • Revenue Growth
  • NAMS 586.97
  • CIVI 22.15
  • 52 Week Low
  • NAMS $14.06
  • CIVI $22.79
  • 52 Week High
  • NAMS $27.29
  • CIVI $74.04
  • Technical
  • Relative Strength Index (RSI)
  • NAMS 52.90
  • CIVI 50.29
  • Support Level
  • NAMS $17.97
  • CIVI $27.40
  • Resistance Level
  • NAMS $19.13
  • CIVI $30.23
  • Average True Range (ATR)
  • NAMS 1.04
  • CIVI 1.40
  • MACD
  • NAMS -0.03
  • CIVI -0.20
  • Stochastic Oscillator
  • NAMS 35.63
  • CIVI 33.87

About NAMS NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.

About CIVI Civitas Resources Inc.

Civitas Resources Inc is an independent exploration and production company engaged in the acquisition, development, and production of oil and associated liquids-rich natural gas in the Rocky Mountain region, in the Denver-Julesburg Basin of Colorado - DJ Basin. The company's operations are focused on developing the horizontal Niobrara and Codell formations that have a low-cost structure, mature infrastructure, production efficiencies, multiple producing horizons, multiple service providers, established reserves, and prospective drilling opportunities.

Share on Social Networks: